Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ginsenoside h
- Development stage
- Phase 2
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ginsenoside H is a preparation derived from Panax ginseng, formulated as "Ginsenoside H dripping pills." It is under clinical investigation primarily as an adjuvant therapy for advanced non-small cell lung cancer. The main active anticancer ingredient in this formulation is ginsenoside Rh2, a dammarane-type saponin (ginsenoside) known for its potential antitumor effects. Ginseng-derived ginsenosides are pharmacologically active compounds with diverse biological activities including immunomodulation, anti-cancer properties, neuroprotection, and metabolic regulation. Mechanistically, certain ginsenosides (including Rh2) modulate ion channels (such as voltage-dependent Ca²⁺/K⁺/Na⁺ channels), inhibit ligand-gated ion channels (e.g., NMDA receptors), and influence apoptosis-related pathways in cancer cells and neurons. The oral route of administration has been studied in clinical trials for the GH formulation[2][7].
- Brand names
- Ginsenoside H dripping pills
- Other names
- GHginsenoside H dripping pillGinsenoside H
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)CaV (Voltage-gated calcium channel protein complex)Kir (Inward-rectifier potassium channels)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ginsenoside h.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ginsenoside h.